Literature DB >> 19844990

Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.

Ulrika Andréasson1, Michael Dictor, Mats Jerkeman, Mattias Berglund, Christer Sundström, Johan Linderoth, Richard Rosenquist, Carl A K Borrebaeck, Sara Ek.   

Abstract

Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis. Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples. Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL. To identify molecular targets associated with the transformation, subsequent immunohistochemistry (IHC) analyses of the corresponding proteins were performed. Using highly purified cells, this study identified 163 genes, which were significantly deregulated during the transformation in a majority of cases. Among the upregulated transcripts, 13 genes were selected for validation using IHC, based on the availability of commercial antibodies, and galectin-3 and NEK2 proteins specifically identify DLBCL-tr, when compared with FL. We demonstrate that by purifying tumor cells through cell sorting, thereby reducing the heterogeneity due to infiltrating cells, it was possible to identify distinct differences between tumor entities rather than variations due to cellular composition. Galectin-3 and NEK2 both identified a subgroup of DLBCL-tr, and the function of these protein markers also suggests a biological role in the transformation process. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844990     DOI: 10.1002/ajh.21549

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 2.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.

Authors:  Karen Dybkær; Martin Bøgsted; Steffen Falgreen; Julie S Bødker; Malene K Kjeldsen; Alexander Schmitz; Anders E Bilgrau; Zijun Y Xu-Monette; Ling Li; Kim S Bergkvist; Maria B Laursen; Maria Rodrigo-Domingo; Sara C Marques; Sophie B Rasmussen; Mette Nyegaard; Michael Gaihede; Michael B Møller; Richard J Samworth; Rajen D Shah; Preben Johansen; Tarec C El-Galaly; Ken H Young; Hans E Johnsen
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

4.  Irreversible Nek2 kinase inhibitors with cellular activity.

Authors:  Jeffrey C Henise; Jack Taunton
Journal:  J Med Chem       Date:  2011-05-31       Impact factor: 7.446

5.  High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Authors:  Hao Wan; Lin Xu; Huangbin Zhang; Feixiang Wu; Weiqiang Zeng; Taiyuan Li
Journal:  J Physiol Biochem       Date:  2020-11-17       Impact factor: 4.158

6.  Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.

Authors:  Mary C Clark; Mabel Pang; Daniel K Hsu; Fu-Tong Liu; Sven de Vos; Randy D Gascoyne; Jonathan Said; Linda G Baum
Journal:  Blood       Date:  2012-10-12       Impact factor: 22.113

7.  Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.

Authors:  C-M Hu; J Zhu; X E Guo; W Chen; X-L Qiu; B Ngo; R Chien; Y V Wang; C Y Tsai; G Wu; Y Kim; R Lopez; A R Chamberlin; E Y-H P Lee; W-H Lee
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

Review 8.  Role of NEK2A in human cancer and its therapeutic potentials.

Authors:  Jiliang Xia; Reinaldo Franqui Machin; Zhimin Gu; Fenghuang Zhan
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

9.  Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.

Authors:  Yan-Ru Zeng; Zhao-Dong Han; Cong Wang; Chao Cai; Ya-Qiang Huang; Hong-Wei Luo; Ze-Zhen Liu; Yang-Jia Zhuo; Qi-Shan Dai; Hai-Bo Zhao; Yu-Xiang Liang; Wei-De Zhong
Journal:  BMC Urol       Date:  2015-08-29       Impact factor: 2.264

10.  Identification of candidate B-lymphoma genes by cross-species gene expression profiling.

Authors:  Van S Tompkins; Seong-Su Han; Alicia Olivier; Sergei Syrbu; Thomas Bair; Anna Button; Laura Jacobus; Zebin Wang; Samuel Lifton; Pradip Raychaudhuri; Herbert C Morse; George Weiner; Brian Link; Brian J Smith; Siegfried Janz
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.